Drug Profile
Gypsetin
Latest Information Update: 30 Jan 1998
Price :
$50
*
At a glance
- Originator Tokyo University of Agriculture and Technology
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 30 Jan 1998 No-Development-Reported for Atherosclerosis in Japan (Unknown route)
- 20 Mar 1995 Preclinical development for Atherosclerosis in Japan (Unknown route)